Introduction
============

*Acinetobacter baumannii (A. baumannii)* are a type of gram-negative non-fermenting bacteria that widely exist in nature and on the surface of human skin. In the presence of a compromised immune system, *A. baumannii* may cause serious infections, including ventilator-associated pneumonia, sepsis, urinary tract infections and meningitis ([@b1-etm-0-0-4242]). Due to the use of invasive operation, broad-spectrum antibiotics and immunosuppressive agents in the last decade, *A. baumannii* has transformed from a monodrug-resistant to a multidrug-resistant or pandrug-resistant organism, and is now becoming the major pathogen of severe fatal nosocomial infections ([@b2-etm-0-0-4242]). Previous results have suggested that numerous mechanisms may lead to this resistance, and the active efflux mechanism is an important factor for mutidrug-resistance in *A. baumannii* ([@b3-etm-0-0-4242]). Since it is the unique efflux pump to *A. baumannii*, the AdeABC system is important in mediating drug-resistance, which belongs to the resistance-nodulation-division multidrug efflux system ([@b4-etm-0-0-4242]).

Therefore, the present study was designed to analyze the association between the differences in the expression level of the efflux pump adeB gene using an *in vitro* induction of a drug-resistance test in *A. baumannii*, and to verify the significance of the efflux mechanism in the induced drug-resistance among the three drugs, respectively. Therefore, research on the mechanisms underlying induced multidrug resistance is aimed at finding a solution to antimicrobial resistance.

Materials and methods
=====================

### Bacterial strains

*A. baumannii* strains that were sensitive to amikacin (n=19), netilmicin (n=17) and imipenem (n=25) were isolated from clinical blood or drainage samples in the First Affiliated Hospital of China Medical University (Shenyang, China) between January 2009 and December 2010. Strains were identified and initial antimicrobial susceptibilities were determined by the Vitek system (BioMérieux, Marcy-l\'Étoile, France). All of the strains were non-repetitive, meaning that only one strain was collected from each patient.

### Instruments and reagents

The instruments that were used for the experiments included a VITEK-2 automated microbial analyzer and Sakuma MIT-P bacterial multipoint inoculator (Sakuma Co., Ltd., Matsudo, Japan). A quantitative polymerase chain reaction (qPCR) kit was purchased from Takara Biotechnology Co., Ltd., Dalian, China. Reference standards of amikacin, netilmicin and imipenem were purchased from The European Pharmacopoeia (EP; Strasbourg, France). Luria-Bertani and Mueller-Hinton (MH) broths and MH agar were purchased from Oxoid Ltd. (Nepean, ON, Canada). AdeB and 16S rRNA primers were synthesized by Sangon Biotech Co., Ltd. (Shanghai, China). RNA extraction kits were purchased from Thermo Fischer Scientific, Inc. (Waltham, MA, USA). Quantitative and reverse transcription PCR kits were purchased from GeneCopoeia, Inc. (Rockville, MD, USA), diethyl pyrophosphate from Tiangen Biotech Co., Ltd. (Beijing, China), and carbonyl cyanide 3-chlorophenylhydrazone (CCCP) and acetone from Sigma-Aldrich (Merck KGaA, Darmstadt, Germany).

### Susceptibility testing

The minimum inhibitory concentration (MIC) values of all the strains to each drug were tested by the broth microdilution assay method, which was recommended by the Clinical and Laboratory Standards Institute (CLSI; 2012) ([@b5-etm-0-0-4242]). A 0.5 McFarland standard bacterial suspension was prepared, which was then diluted using MH broth (10-fold and twice) and were placed in the 96-well plates at different concentrations. The *A. baumannii* strains that were sensitive to amikacin (n=19), netilmicin (n=17) and imipenem (n=25) were selected for this experiment according to the CLSI standards (2012) ([@b5-etm-0-0-4242]). Furthermore, *Pseudomonas aeruginosa* (*P. aeruginosa*) ATCC27853 and *Escherichia coli* ATCC29522 were both used as control strains.

### Multi-step stable in vitro induction of drug-resistance

Selective medium containing an appropriate concentration of one antibiotic and MH broth was prepared in a 96-well plate. The initial concentration of the antibiotic was half of the MIC of the testing strains. The final concentration of bacterial suspension was 4--8×10^5^ colony forming units/ml. In total a volume of 200 µl was prepared in each well of the 96-well plate, and each well contained 100 µl antimicrobial solution and 100 µl bacterial suspension. The suspension was inoculated into the MH broth medium with ascending concentrations of antimicrobial drugs, until the drug concentration reached 128 µg/ml. The 128 µg/ml was then selected as the final concentration for induction. The resistant strains were cultured another five times at this final concentration. Next, the surviving strains were transferred to the drug-free broth medium and inoculated twice to maintain resistant stability. Then the resistant strains were re-inoculated in the media with a drug concentration of 128 mg/l. The surviving strains were considered to have stable drug-resistance. Finally, the stably resistant strains were inoculated on a blood plate to preserve the strains. When the strains grew poorly, the induction was repeated with the same or reduced concentration. If there was no growth for two generations (the same concentration) the strains were discarded. In addition, the drug-free and strain-free control broth wells and the culture in the blood plate were also established. Finally, the duration of induction for each drug was \~4 weeks.

### Detection of an efflux phenotype

The 2-fold agar dilution method, recommended by the 2012 CLSI, was used for this experiment. The MIC values of amikacin, netilmicin and imipenem were detected. Meanwhile, the MH agar containing CCCP was prepared. CCCP was fully dissolved in 10 µg/ml acetone and the solution was passed through a sterile filter (0.22-µm; Bioer, Hangzhou, China). The final concentration of CCCP was 10 µg/ml in which the strains could survive. The criteria for a positive efflux phenotype were defined as a MIC value with CCCP that decreased 4-fold or more compared to the MIC values without CCCP ([@b6-etm-0-0-4242]). Both the sensitive and resistant groups were used for the test, and *P. aeruginosa* ATCC27853 was selected for the quality control strain.

### Detection of the expression level of efflux pump gene adeB by qPCR

Following bacterial RNA extraction, the total RNA was reverse transcribed into cDNA and RT-qPCR was performed. AdeB was the target gene and 16S rRNA served as an internal reference gene ([@b4-etm-0-0-4242]). The reaction was 20 µl in total: 10 µl 2X All-in-one qPCR mix, 2 µl PCR forward and 2 µl PCR reverse primers, 2 µl cDNA templates, 0.4 µl 50X Rox Reference Dye and 3.6 µl purified water. The reaction conditions consisted of three phases: Predenaturation at 95°C for 10 min; 40 cycles of denaturation at 95°C for 10 sec, annealing at 55°C for 20 sec, extension at 72°C for 15 sec; and one cycle of dissociation at 95°C for 10 sec. For both the target and the internal reference genes, RT-qPCR reactions were conducted in two tubes simultaneously, and each reaction was repeated six times. The results were analyzed by the ∆∆Cq method ([@b7-etm-0-0-4242]). One positive strain (for adeB) was selected for the control sample. Standardization was made by the subtraction of the mean Cq value of each adeB gene and the mean Cq value of the corresponding 16S rRNA (repeated three times for each sample), yielding a corrected ∆Cq value. Following correction, subtraction of the ∆Cq value of the resistant strain from the mean ∆Cq value of the positive strain yielded ∆∆Cq. Finally, the relative mRNA expression level of the adeB gene in the resistant strain was calculated using the 2^−∆∆Cq^ method.

Results
=======

### In vitro induction of drug-resistance

There were 19, 17 and 25 strains (sensitive to amikacin, netilmicin and imipenem, respectively) selected for *in vitro* induction under a single drug-condition. All the MICs of the 19 amikacin-sensitive strains were no more than 16 µg/ml, 17 netilmicin-sensitive strains were no more than 8 µg/ml and for the 25 imipenem-sensitive strains were ≤4 µg/ml. Following the *in vitro* induction test, 11, 15 and 8 resistant strains were generated with stable mutations, respectively. Among them, the imipenem-resistant group had the longest induction time.

### Result of the efflux phenotype

The MIC values of all the sensitive strains decreased less than 2-fold under CCCP-containing conditions for the three drugs, demonstrating the negative efflux phenotype. On the other hand, there were 10 strains resistant to amikacin showing decreased MIC values for 4-fold or more after addition of CCCP, 14 strains for netilmicin but none for imipenem. All the strains grew well on the MH plates containing only CCCP. Furthermore, decreased MIC values for 4-fold or more with CCCP showed a significant efflux pump phenotype. The details of the efflux pump phenotype are listed in [Table I](#tI-etm-0-0-4242){ref-type="table"}.

### Results of the adeB gene expression levels by RT-qPCR

The amplification curves of the target and the internal reference genes were all presented as typical S-shape kinetic curves, with evident exponential and plateau phases. The corresponding melting curves only had a single peak, indicating good specificity. Furthermore, no adeB gene expression was observed in any of the initially susceptible strains or the imipenem-resistant group. The expression levels of all the internal reference 16S rRNA standards were good. Furthermore, there were 10 and 5 strains, respectively, for the amikacin- and netilmicin-resistant groups, as shown in [Table II](#tII-etm-0-0-4242){ref-type="table"} and [Fig. 1](#f1-etm-0-0-4242){ref-type="fig"}. In addition, the electrophoretograms of the strains with positive expression of the efflux pump adeB gene are shown in [Fig. 2](#f2-etm-0-0-4242){ref-type="fig"}, in which lanes 1--10 showed the results from the strains in the amikacin-resistant group and the last five lanes show the results from strains 3, 5, 11, 13 and 15 of the netilmicin-resistant group. These data indicated different copy number between the groups; specifically, the netilmicin-resistant groups had a higher copy number.

Discussion
==========

*A. baumannii* has evolved from being mono- to multi-drug resistant or even into a pandrug-resistant organism. They have become a major pathogen involved in serious and fatal nosocomial infections, which is an important global issue ([@b8-etm-0-0-4242]). Previous studies show that the resistant mechanisms of *A. baumannii* include formation of inactivated enzymes, gene mutations in chromosomes, changes in outer membrane porins and the active drug efflux mechanism ([@b6-etm-0-0-4242],[@b9-etm-0-0-4242],[@b10-etm-0-0-4242]). Among these, the active efflux mechanism is the main factor causing multi-drug resistance. Since the AdeABC-type active efflux system in *A. baumannii* BM4454 ([@b3-etm-0-0-4242]) was discovered by French researchers in 2001, a greater number of studies on the mechanisms of multi-drug resistance in *A. baumannii* have focused on active efflux. Although AdelJK, AdeDE, AdeFGH and other systems have been studied in recent years, the AdeABC-type active efflux system still remains unique and most closely associated to *A. baumannii* ([@b11-etm-0-0-4242],[@b12-etm-0-0-4242]).

As an inhibitor of the efflux systems, CCCP can freely diffuse across both sides of the lipid membrane. CCCP is a strong uncoupler that transmits protons to destroy the transmembrane electrochemical gradient, resulting in a loss of energy supply for transport proteins. CCCP can damage the active effects of the efflux system, increase drug accumulation in bacteria and recover the susceptibility of bacteria to drugs ([@b13-etm-0-0-4242]). A previous study on active efflux pump inhibitors by Chinese researchers has demonstrated that their reported inhibitory effects are different to the presently reported effects ([@b6-etm-0-0-4242]), but it is not clear how suitable CCCP is as an inhibitor for screening the AdeABC efflux pump in *A. baumannii* and the difference between different antibiotics.

The results of the present *in vitro* induction of drug-resistance tests demonstrate that amikacin and netilmicin are more prone to producing drug-resistance mutations than imipenem. Following induction by amikacin, netilmicin and imipenem *in vitro*, there were 10, 14 and 0 resistant strains inhibited by CCCP, respectively. MIC values decreased 4-fold or more after addition of the efflux pump inhibitor, CCCP. The most notable changes were in the amikacin- and netilmicin-resistant groups with 11 and 15 breakpoints, respectively, indicating a marked efflux effect. These results demonstrate that amikacin and netilmicin are more likely to produce resistance caused by the AdeABC-type efflux system than imipenem *in vitro*. There were 15 strains that showed a positive efflux phenotype in netilmicin-resistant groups, but the expression of the adeB gene was detected only in 5 of all the 15 strains. In addition, the MIC value of strain no. 8 decreased 15 breakpoints when accompanied with CCCP, but its copy number was only 55.7152, as shown by RT-qPCR. Those results indicate the difference between different drugs in inducing resistance, and the application of CCCP for inhibition of efflux systems in different drugs.

The results demonstrated that among the drug-resistant strains that were induced *in vitro*, 10 and 5 strains expressed the adeB gene in the amikacin- and netilmicin-resistant groups, respectively. RT-qPCR fluorescence quantitative detection of resistant strains demonstrated that netilmicin-resistant strain no. 5 had a higher mRNA level of the adeB efflux pump and its copy number reached 128.2903. Furthermore, amikacin-resistant strain nos. 1, 5, 6, 9 and 10 and netilmicin-resistant strain no. 3 had lower mRNA levels of the adeB efflux pump. The copy number of amikacin-resistant strain no. 1 was 10.6294, which was significantly lower than that of other strains. These results indicate that there are differences in the efficacy of common clinically used antimicrobial drugs due to the AdeABC efflux system in different strains. The induction time of netilmicin strain no. 5 was 13 days and the amikacin strain no. 1 was 19 days. Therefore, we can conclude that the induction time has no direct association with the expression of adeB. Furthermore, no expression of the adeB was detected by qPCR in initially susceptible strains, indicating that the active efflux mechanism is important in mediating the induction of drug resistance in *A. baumannii* ([@b14-etm-0-0-4242]--[@b18-etm-0-0-4242]). There were a number of differences between the adeB expression results and the number of *in vitro* induction of resistant strains. These findings indicate that drug-resistant strains possess efflux pump mechanisms or important resistance mechanisms other than the AdeABC efflux system, including extended-spectrum β-lactamases enzymes and changes in and loss of membrane permeability, all of which need to be studied further. By contrast to the reports on the mechanisms of carbapenem-resistance in *A. baumannii*, the resistance mechanisms have regional differences that may be caused by a different phenotype or genotype of the clinically collected strains ([@b19-etm-0-0-4242]--[@b21-etm-0-0-4242]).

The present study used an *in vitro* drug-induction test to confirm that susceptible *A. baumannii* could develop a drug-resistance following long-term exposure at low doses of antimicrobial drugs. In addition, the presence of an active efflux mechanism and the involvement of other mechanisms in drug resistance induction also increase the resistance against commonly used clinical antimicrobial drugs. Therefore, the rational use of antimicrobial drugs and strengthened management of treatment regimens can reduce or avoid formation of drug-resistant strains and evolution of resistance. Therefore, rational antibiotic use is an important risk management strategy used to prevent and reduce opportunistic pathogen infections in hospitals, and the development of drug-resistance.
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###### 

Detection of efflux phenotype of *in vitro*-induced isolates by three drugs.

        MIC (µg/ml)   MIC (µg/ml)   MIC (µg/ml)                     
  ----- ------------- ------------- ------------- ----------- ----- ---------
    1   256           256           256             64        512   128
    2   256           128           256             64        512   128
    3   256           256           256             64        512   128
    4   256           256           256           256         512   128
    5   256           256           256             16        512   128
    6   256           256           256             32        512   128
    7   256           256           256             32        512   128
    8   256           256           256             32        512   \<0.015
    9                               256             32        512   128
  10                                256             64        512   128
  11                                256                 0.5   128   128
  12                                256             64              
  13                                256             64              
  14                                256             64              
  15                                256             64              

MIC, minimum inhibitory concentration; CCCP, carbonyl cyanide 3-chlorophenylhydrazone.

###### 

Detection of the expression levels of the active efflux pump gene adeB in the amikacin and netilmicin mutation groups by RT-qPCR.

                  Cq      Cq      ΔCq    ΔΔCq    
  --------------- ------- ------- ------ ------- ----------
  Amikacin 1      27.26   21.32   5.94   −3.41   10.6294
  Amikacin 2      19.09   14.74   4.35   −5.00   32.0000
  Amikacin 3      19.35   14.87   4.48   −4.87   29.2426
  Amikacin 4      24.46   20.66   3.80   −5.55   46.8507
  Amikacin 5      24.32   20.13   4.29   −4.56   23.5883
  Amikacin 6      22.36   17.02   5.34   −4.61   24.4201
  Amikacin 7      19.54   15.48   4.06   −5.29   39.1244
  Amikacin 8      25.42   21.87   3.55   −5.80   55.7152
  Amikacin 9      19.87   15.20   4.67   −4.68   25.6342
  Amikacin 10     23.87   19.29   4.58   −4.77   27.2843
  Netilmicin 3    19.61   15.75   4.86   −4.49   22.4711
  Netilmicin 5    19.50   17.16   2.34   −7.01   128.2903
  Netilmicin 11   21.82   17.82   4.00   −5.35   40.7859
  Netilmicin 13   20.16   15.86   4.30   −5.05   33.1284
  Netilmicin 15   20.81   17.46   3.35   −6.00   64.0000

Control group A was PRABA (*Pandrug-resistant Acinetobacter baumannii*), and the fluorescent reverse transcription-quantitative polymerase chain reaction Cq values of adeB and 16S rRNA genes were 24.81 and 15.46, ΔCq=9.35, respectively.
